-
公开(公告)号：US20170057981A1
公开(公告)日：2017-03-02
申请号：US15254342
申请日：2016-09-01
Applicant: AbbVie Inc.
Inventor： Hui-Ju J. Chen , David A. DeGoey , John Hartung , Nathan Ide , Vikram Kalthod , Allan C. Krueger , Yi-Yin Ku , Tongmei Li , John T. Randolph , Rolf Wagner , Jaclyn Chau , Geoff T. Halvorsen , Christopher C. Marvin , Eric Voight
IPC: C07F9/08
CPC classification number: C07F9/08 , C07F9/6512 , C07H19/10
Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 本发明的特征在于有效抑制丙型肝炎病毒（“HCV”）聚合酶的活性的化合物。 本发明还涉及制备这些化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20150218194A1
公开(公告)日：2015-08-06
申请号：US14683910
申请日：2015-04-10
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: C07F9/6558 , C07D405/14 , C07D403/14 , C07D401/14 , C07D207/09 , C07D491/113 , C07D413/14 , C07D471/04 , C07C201/06 , C07D207/08 , C07D207/16 , C07D417/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US09006387B2
公开(公告)日：2015-04-14
申请号：US14180886
申请日：2014-02-14
Applicant: AbbVie, Inc.
Inventor： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger
IPC: C07K16/00 , A61K38/00 , C07K5/06 , C07D401/14 , C07D403/14 , C07D417/14 , C07C33/26 , C07C205/19
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20150087618A1
公开(公告)日：2015-03-26
申请号：US14558318
申请日：2014-12-02
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: C07F7/02 , C07D405/14 , C07D403/14 , C07D401/14 , C07D413/14
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20150056164A1
公开(公告)日：2015-02-26
申请号：US14260504
申请日：2014-04-24
Applicant: AbbVie Inc.
Inventor： David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC: C07D409/10 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K45/06 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/54 , A61K31/18
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。
-
Patent Agency Ranking
公开(公告)号：US20130303547A1
公开(公告)日：2013-11-14
申请号：US13944447
申请日：2013-07-17
Applicant: AbbVie Inc.
Inventor： Brian E. Green , David D. Anderson , Todd D. Bosse , Curt S. Cooper , Larry L. Klein , Allan C. Krueger , Daniel P. Larson , Dachun Liu , Keith F. McDaniel , Christopher E. Motter , John K. Pratt , Todd W. Rockway , Teresa A. Rosenberg , Ming C. Yeung , Hui-Ju Chen , Jason P. Shanley
IPC: C07D403/12 , C07D409/14 , C07D403/14 , C07D207/16 , C07D241/24
CPC classification number: C07D403/12 , C07D207/16 , C07D241/24 , C07D403/14 , C07D409/14 , C07K7/02
Abstract: This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.
Abstract translation: 本发明涉及：（a）式I化合物及其盐，其特别可用作丙型肝炎病毒（HCV）抑制剂; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的药物组合物; 和（d）使用这些化合物，盐和组合物的方法。
-
公开(公告)号：US20230285378A1
公开(公告)日：2023-09-14
申请号：US17941090
申请日：2022-09-09
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Warren M. Kati , Tammie K. Jinkerson , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/454 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07D403/14 , C07F7/02 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , A61K31/435
CPC classification number: A61K31/454 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07D403/14 , C07F7/02 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , A61K31/435 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20180022763A1
公开(公告)日：2018-01-25
申请号：US15588037
申请日：2017-05-05
Applicant: AbbVie Inc.
Inventor： Jaclyn Chau , Hui-Ju J. Chen , David A. DeGoey , John Hartung , Nathan Ide , Vikram Kalthod , Allan C. Krueger , Yi-Yin Ku , Tongmei Li , John T. Randolph , Rolf Wagner , Geoff T. Halvorsen , Christopher C. Marvin , Eric Voight , Brian S. Brown , Steven R. Martinez , Anurupa Shrestha , Howard R. Heyman
IPC: C07F9/08 , C07F9/6512 , C07H19/10
CPC classification number: C07F9/08 , C07F9/6512 , C07H19/10
Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US09676797B2
公开(公告)日：2017-06-13
申请号：US15254342
申请日：2016-09-01
Applicant: AbbVie Inc.
Inventor： Hui-Ju J. Chen , David A. DeGoey , John Hartung , Nathan Ide , Vikram Kalthod , Allan C. Krueger , Yi-Yin Ku , Tongmei Li , John T. Randolph , Rolf Wagner , Jaclyn Chau , Geoff T. Halvorsen , Christopher C. Marvin , Eric Voight
IPC: A61K31/675 , C07F9/02 , C07F9/08 , C07F9/6512
CPC classification number: C07F9/08 , C07F9/6512 , C07H19/10
Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20170157105A1
公开(公告)日：2017-06-08
申请号：US15434789
申请日：2017-02-16
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/695
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.055 seconds)
